SAB BIOTHERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $1.3M | $2.2M | $23.9M | $60.9M | $55.2M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $34.4M | $30.3M | $16.5M | $36.4M | $57.2M | $27.9M |
| SG&A Expense | $14.6M | $14.0M | $23.8M | $16.4M | $17.1M | $6.8M |
| Operating Income | $-49.0M | $-42.9M | $-38.1M | $-28.9M | $-13.4M | $20.6M |
| Operating Margin | — | -3,244.9% | -1,700.6% | -121.0% | -22.0% | 37.2% |
| Interest Expense | — | — | $315.3K | $301.6K | $294.5K | $469.2K |
| Pretax Income | $13.3M | — | $-42.2M | $-18.7M | $-17.1M | $20.1M |
| Income Tax Expense | $0 | $0 | $0 | $25.6K | $0 | $0 |
| Net Income | $13.3M | $-34.1M | $-42.2M | $-18.7M | $-17.1M | $20.1M |
| Net Margin | — | -2,579.0% | -1,884.5% | -78.4% | -28.2% | 36.4% |
| EPS (Basic) | $0.22 | $-0.53 | $-1.09 | $-0.62 | $-0.09 | $0.11 |
| EPS (Diluted) | $-0.79 | $-0.53 | $-1.09 | $-0.62 | $-0.09 | $0.11 |
| Shares Outstanding (Basic) | 19.3M | 64.8M | 38.7M | 30.5M | 191.4M | 177.7M |
| Shares Outstanding (Diluted) | 61.3M | 64.8M | 38.7M | 30.5M | 191.4M | 189.1M |
| Dividends Per Share | — | — | — | — | — | — |